<DOC>
	<DOCNO>NCT00128531</DOCNO>
	<brief_summary>The purpose study look efficacy safety leuprolide acetate patient prostate cancer .</brief_summary>
	<brief_title>Leuprolide Acetate 3.75 mg Depot Treat Prostate Cancer</brief_title>
	<detailed_description>Other assessment include evaluation main leuprolide PK parameters 12 subject administration 3 dos . Study Design : This multi-center , open-label , fixed investigation six monthly dosage leuprolide acetate 3.75 mg administer patient histologically proven carcinoma prostate , might benefit medical androgen deprivation therapy . A total 120 male patient receive single , i.m . injection leuprolide acetate 3.75 mg initially study day 0 ( baseline assessment ) monthly ( i.e . every 28 day ) five month . 12 patient also plasma leuprolide level measure PK analysis first 3 injection period ( PK group ) . These patient belong pre-defined study site .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Males &gt; /= 18 year age , histologically proven carcinoma prostate , might benefit medical androgen deprivation therapy Life expectancy least 1 year World Health Organization/Eastern Cooperative Oncology Group ( WHO/ECOG ) performance status 0 , 1 , 2 Adequate renal function screening define serum creatinine &lt; /= 1.6 time ULN ( upper limit normal ) clinical laboratory Adequate stable hepatic function define bilirubin &lt; /= 1.5 time ULN transaminase ( i.e . SGOT , SGPT ) &lt; /= 2.5 time ULN clinical laboratory screen Ability comprehend full nature purpose study , include possible risk side effect ; ability cooperate Investigator comply requirement entire study Signed write informed consent prior inclusion study Evidence brain metastasis , opinion Investigator , take account medical history , clinical observation symptom Evidence spinal cord compression , opinion Investigator , take account medical history , clinical observation symptom Evidence severe urinary tract obstruction threaten urinary retention , opinion Investigator , take account medical history , clinical observation symptom Excruciating , severe pain extensive osseous deposit , opinion Investigator , take account medical history , clinical observation symptoms Testosterone level &lt; 1.5 ng/mL screening , locally determine laboratory clinical site Previous cancer systemic therapy chemotherapy , immunotherapy ( e.g . antibody therapy , tumorvaccines ) , biological response modifier ( e.g . cytokine ) within 3 month baseline Previous hormonal therapy treatment prostate cancer , luteinising hormonereleasing hormone ( LHRH ) analogue ( e.g . Lupron® , Zoladex® , etc . ) [ washout allow ] Previous treatment androgen receptor ( AR ) blocker , Casodex® , Fugerel® , Megace® , Androcur® ( washout allow ) Previous orchiectomy , adrenalectomy hypophysectomy Previous prostatic surgery ( e.g . radical prostatectomy , transurethral resection prostate [ TURP ] ) within 2 week baseline Previous local therapy primary tumor curative attempt surgery ( external beam radiotherapy , brachytherapy , thermotherapy , cryotherapy ) within 2 week baseline Any investigational drug within 5 halflives physiological action 3 month ( whichever longer ) baseline Administration 5alphareductase inhibitor ( Proscar® , Avodart® , Propecia® ) within 3 month baseline Overthecounter ( OTC ) alternative medical therapy estrogenic antiandrogenic effect ( i.e. , PCSPES , saw palmetto , Glycyrrhiza® , Urinozinc® , dehydroepiandrosterone [ DHEA ] ) within 3 month baseline Hematological parameter ( RBC , total differential WBC count , platelet count , hemoglobin , hematocrit ) outside 20 % upper low limit normal ( ULN , LLN ) clinical laboratory screen Coexistent malignancy , accord Investigator 's opinion Uncontrolled congestive heart failure , myocardial infarction coronary vascular procedure ( e.g . balloon angioplasty , coronary artery bypass graft ) significant symptomatic cardiovascular disease ( ) within 6 month baseline ; rest uncontrolled hypertension : ( &gt; /= 160/100 mmHg ) symptomatic hypotension within 3 month baseline Venous thrombosis within 6 month baseline Insulindependent diabetes mellitus History drug and/or alcohol abuse within 6 month baseline Serious concomitant illness ( e ) disease ( ) [ e.g. , hematological , renal , hepatic , respiratory , endocrine , psychiatric ] may interfere , put patient additional risk , ability receive treatment outline protocol Patients receive anticoagulant prothrombin partial thromboplastin time outside normal range laboratory assay ; patient anticoagulation antiplatelet medication ( e.g . dipyridamole , ticlopidine , warfarin derivative ) receive stable dose 3 month baseline ; patient receive warfarinderivative anticoagulant International Normalized Ratio ( INR ) therapeutic range clinical indication anticoagulant prescribe . Blood donations/losses within 2 month baseline , apart previous prostatic surgery patient ( see early exclusion [ 9 ] ; please note patient include pharmacokinetic [ PK ] group ) Known hypersensitivity GnRH , GnRH agonist , include LHRH analogue , excipients study formulation History follow prior study : immunization ( within 4 week baseline ) ; flu shot ( within 2 week baseline ) ; anaphylaxis ; skin disease would interfere injection site evaluation ; dermatographism document screen follow treatment .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Phase III</keyword>
	<keyword>open label</keyword>
	<keyword>multiple dose</keyword>
	<keyword>safety study</keyword>
	<keyword>pharmacokinetic study</keyword>
	<keyword>efficacy study</keyword>
</DOC>